Eli Lilly's Taltz set to reach blockbuster status by 2020, analyst predicts
US drug major Eli Lilly’s (NYSE: LLY) Taltz (ixekizumab) for plaque psoriasis is set to achieve blockbuster status by 2022, an analyst has predicted.
The drug, which was approved by the US Food and Drug Administration in March this year, will generate sales in excess of $1 billion, according to research and consulting firm GlobalData. Taltz is one of an influx of novel treatments outside mainstay anti-tumor necrosis factor (anti TNF) therapies, including Novartis’ (VTX: NOVN) Cosentyx (secukinumab).
Alexandra Annis, GlobalData’s immunology analyst, said: “Taltz has a shared mechanism of action with Cosentyx and although it will be competing with Cosentyx, which has a significant first-to-market advantage, Taltz offers more convenient dosing.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze